BETA-2 ADRENERGIC AGONISTS FOR THE TREATMENT OF SISTEMIC LUPUS ERYTHEMATOSOUS (SLE) AND SLE-DERIVED SYMPTOMS AND MANIFESTATIONS

The invention is related to the new use of beta-2 adrenergic agonists, and more specifically of long-acting Beta-2 adrenergic agonists (LABA) or an ultra-long-acting Beta-2 adrenergic agonists (ultra-LABA)suchas clenbuterol, in the prevention and treatment of SLE and SLE-derived symptoms and patholo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	ARAN PERRAMON, Josep, LUQUE GÓMEZ, Ana
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention is related to the new use of beta-2 adrenergic agonists, and more specifically of long-acting Beta-2 adrenergic agonists (LABA) or an ultra-long-acting Beta-2 adrenergic agonists (ultra-LABA)suchas clenbuterol, in the prevention and treatment of SLE and SLE-derived symptoms and pathologic manifestations. L'invention concerne la nouvelle utilisation d'agonistes bêta 2 adrénergiques, et plus particulièrement d'agonistes bêta 2 adrénergiques à action prolongée (LABA) ou un agoniste bêta 2 adrénergique à action ultra-longue (ultra-LABA) tel que le clenbutérol, dans la prévention et le traitement du lupus érythémateux disséminé et des symptômes dérivés du LED et des manifestations pathologiques.